Pfizer Inc. announced on Thursday that it will move forward with the testing of its modified version of the once-daily weight loss drug danuglipron. The drugmaker said it had looked at several options and picked danuglipron based on the results of its ongoing pharmacokinetic study. In December, Pfizer discontinued a twice-daily regimen of danuglipron after patients in the study struggled with tolerating the drug in a mid-stage study. "Obesity is ...